
- BioPharm International-03-15-2021
- Volume 2021 eBook
- Issue 1
Gene Therapies Target Neurodegenerative Diseases
A growing pipeline of gene therapy candidates aimed at treating neurodegenerative diseases has prompted new guidance.
Much of gene therapy development is targeting neurodegenerative diseases, among other difficult-to-treat indications. Responding to a growing pipeline of gene therapy candidates, FDA released a new draft guidance in January 2021, Human Gene Therapy for Neurodegenerative Diseases, focused on gene therapies being developed to treat neurodegenerative diseases. The new draft guidance focuses on product development, preclinical testing, and clinical trial design as well as discusses marketing approval pathways for investigational gene therapy products for neurodegenerative disease indications.
Article Details
BioPharm International
eBook: Regulatory Sourcebook, March 2021
March 2021
Pages: 12–13
Citation
When referring to this article, please cite it as F. Mirasol, “Gene Therapies Target Neurodegenerative Diseases," BioPharm International Regulatory Sourcebook eBook (March 2021).
Articles in this issue
over 4 years ago
It Takes a Bio/Pharma Villageover 4 years ago
Collaborative Efforts Address Key Data Integrity Challengesover 4 years ago
Can FDA Reinvent Inspections?over 4 years ago
Growing Pipeline of Antisense Oligonucleotides Prompts Guidanceover 4 years ago
A Real-World Approach to Evaluating Cleanroom Garmentsover 4 years ago
FDA 2021 Guidance Agenda Sees Focus on Genericsover 4 years ago
Regulatory and Standard Setting Organizations DirectoryNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.